1. AtaiBeckley added to NASDAQ Biotechnology Index on December 22, 2025. 2. Company raised $300 million, advancing clinical programs toward late-stage development. 3. Strategic combination with Beckley Psytech enhances leadership in mental health therapeutics. 4. Company focuses on treatment-resistant depression and social anxiety disorder therapies. 5. U.S. redomiciliation expected to foster long-term growth and shareholder value.
FAQ
Why Bullish?
Inclusion in the NBI boosts credibility and attracts institutional investment. Historically, companies added to indices often see positive price momentum.
How important is it?
Addition to a prominent index signifies potential for increased investor interest and market visibility.
Why Long Term?
The strategic initiatives and redomiciliation aim for sustained operational growth. Previous examples like inclusion in major indices leading to long-term price gains further support this.
Atai Beckley N.V. Added to NASDAQ Biotechnology Index (NBI)
NEW YORK and AMSTERDAM, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI), a clinical-stage biopharmaceutical company focused on revolutionizing mental health treatment, has announced the inclusion of its common stock in the NASDAQ Biotechnology Index (NBI), effective before market open on December 22, 2025.
Significant Milestones for Atai Beckley in 2025
2025 has marked a pivotal year for ATAI, characterized by substantial advancements across its corporate pipeline and strategic foundation. Srinivas Rao, Chief Executive Officer of Atai Beckley, stated, “We strengthened our balance sheet by raising approximately $300 million, advanced multiple clinical programs toward late-stage development, and deepened our leadership in next-generation mental health therapeutics through our strategic merger with Beckley Psytech.” He further noted that the upcoming corporate redomiciliation to the U.S. is expected by year-end.
Importance of Inclusion in the NASDAQ Biotechnology Index
The NBI tracks a select group of securities listed on The Nasdaq Stock Market that are classified under the biotechnology sector according to the Industry Classification Benchmark (ICB). This index employs a modified capitalization-weighted methodology, ensuring that member companies meet strict eligibility criteria, including:
- Minimum market capitalization
- Average daily trading volume
- Time as a public company
Attaining a position in the NBI not only validates Atai Beckley's business model but also boosts visibility among investment managers and institutional investors. The index serves as a benchmark for active investment strategies and is reassessed annually in December.
About Atai Beckley's Clinical Pipeline
Atai Beckley is dedicated to transforming patient outcomes through the development of effective and scalable mental health treatments. The company was formed through the strategic merger of ATAI Life Sciences N.V. and Beckley Psytech Limited in November 2025. The pipeline includes:
- BPL-003 - a mebufotenin benzoate nasal spray for treatment-resistant depression (TRD)
- VLS-01 - a DMT buccal film for TRD
- EMP-01 - (R)-MDMA HCl for social anxiety disorder, all currently in Phase 2 clinical trials
Additionally, the company is exploring novel, non-hallucinogenic 5-HT2AR agonists aimed at treating both opioid use disorder and TRD.
Stay Updated on Atai Beckley
For the latest updates on Atai Beckley and its mission to innovate mental health care, visit www.ataibeckley.com or follow the company on LinkedIn and X.
Forward-Looking Statements
This announcement contains forward-looking statements under the Private Securities Litigation Reform Act of 1995. These statements may involve risks and uncertainties that could cause actual results to differ materially from our projections. Specific factors impacting results are detailed in the "Risk Factors" section of our most recent Annual Report on Form 10-K filed with the SEC.
Contact Information
For investor inquiries, please contact: IR@ataibeckley.com
For media inquiries, please contact: PR@ataibeckley.com